Versant Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Versant Capital Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12	Closed	-$1K	–	1776
2019 Q1	$1K	Hold	12	–	–	﹤0.01%	1508
2018 Q4	$1K	Hold	12	–	–	﹤0.01%	1420
2018 Q3	$2K	Sell	12 -46	-79%	-$10.9K	﹤0.01%	1351
2018 Q2	$13K	Sell	58 -14	-19%	-$3.75K	0.01%	818
2018 Q1	$17K	Sell	72 -5	-6%	-$1.31K	0.01%	703
2017 Q4	$23K	Buy	77 +28	+57%	+$9.21K	0.01%	597
2017 Q3	$18K	Buy	+49	New	+$17.4K	0.01%	645

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Versant Capital Management's DMK Position: Q2 2019 in Review

Versant Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2019, closing a stake of 12 shares — an estimated $1K sold.

Versant Capital Management first reported a position in DMK in Q3 2017 and held it in 7 quarters. The position peaked at $23K in Q4 2017. 51 funds tracked by Wall St. Rank hold DMK as of Q2 2019.

Versant Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2019 after selling out during the quarter.
Versant Capital Management sold 12 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2019, an estimated $1K.
Versant Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2017 and held it in 7 quarters.
Versant Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $23K in Q4 2017.
51 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2019.

Based on Versant Capital Management's 13F filing for Q2 2019, filed 16 Jul 2019.